Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.

Nature | 2011

Notch signalling is a central regulator of differentiation in a variety of organisms and tissue types. Its activity is controlled by the multi-subunit γ-secretase (γSE) complex. Although Notch signalling can play both oncogenic and tumour-suppressor roles in solid tumours, in the haematopoietic system it is exclusively oncogenic, notably in T-cell acute lymphoblastic leukaemia, a disease characterized by Notch1-activating mutations. Here we identify novel somatic-inactivating Notch pathway mutations in a fraction of patients with chronic myelomonocytic leukaemia (CMML). Inactivation of Notch signalling in mouse haematopoietic stem cells (HSCs) results in an aberrant accumulation of granulocyte/monocyte progenitors (GMPs), extramedullary haematopoieisis and the induction of CMML-like disease. Transcriptome analysis revealed that Notch signalling regulates an extensive myelomonocytic-specific gene signature, through the direct suppression of gene transcription by the Notch target Hes1. Our studies identify a novel role for Notch signalling during early haematopoietic stem cell differentiation and suggest that the Notch pathway can play both tumour-promoting and -suppressive roles within the same tissue.

Pubmed ID: 21562564 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: 1P01CA97403
  • Agency: NCI NIH HHS, United States
    Id: R01 CA133379
  • Agency: NCI NIH HHS, United States
    Id: R01CA133379
  • Agency: NCI NIH HHS, United States
    Id: R21CA141399
  • Agency: NCI NIH HHS, United States
    Id: R01 CA149655
  • Agency: NCI NIH HHS, United States
    Id: R01CA1328234
  • Agency: NCI NIH HHS, United States
    Id: R21 CA141399-02
  • Agency: NCI NIH HHS, United States
    Id: R21 CA141399
  • Agency: NCI NIH HHS, United States
    Id: R01CA149655
  • Agency: NCI NIH HHS, United States
    Id: R01 CA105129-07
  • Agency: Howard Hughes Medical Institute, United States
  • Agency: NCI NIH HHS, United States
    Id: R01 CA149655-03
  • Agency: NCI NIH HHS, United States
    Id: U54 CA143798
  • Agency: NCI NIH HHS, United States
    Id: P01 CA097403
  • Agency: NCI NIH HHS, United States
    Id: R01 CA105129
  • Agency: NCI NIH HHS, United States
    Id: R01 CA133379-04
  • Agency: NCI NIH HHS, United States
    Id: U54CA143798
  • Agency: NCI NIH HHS, United States
    Id: R01CA105129

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Broad Institute (tool)

RRID:SCR_007073

Biomedical and genomic research center located in Cambridge, Massachusetts, United States. Nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals. Dedicated to advance understanding of biology and treatment of human disease to improve human health.

View all literature mentions